Our study is the first to report the potential of brazilin from Caesalpinia sappan herb as a natural compound for the development of novel PCSK9 inhibitor, which could lead to new hypercholesterolemia drugs by disrupting the interaction between PCSK9 and LDLR. This evidence concerns the gene LDLR and Hypercholesterolemia.